WASHINGTON (dpa-AFX) - Boston Scientific Corp. (BSX) announced two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm PROMUS Element Everolimus-Eluting Platinum Chromium, or PtCr, Stent System in treating de novo coronary lesions in small coronary vessels.
The PLATINUM Small Vessel study previously met its primary endpoint of target lesion failure, or TLF, at 12 months with a rate of 2.4 percent for the 2.25 mm PROMUS Element Stent compared to a pre-specified performance goal of 21.1 percent based on historical outcomes for the 2.25 mm TAXUS Express Paclitaxel-Eluting Stent. The TLF rate at two years was 4.7 percent with the 2.25 mm PROMUS Element Stent while the rate of target lesion revascularization, or TLR, was 2.5 percent.
According to Boston Scientific, rates of other major adverse events remained low in patients treated with study stents at two years, including cardiac death, myocardial infarction and Academic Research Consortium definite/probable stent thrombosis. There were no deaths between 1 and 2 years for patients treated with the 2.25 mm PROMUS Element Stent.
Ian Meredith, professor and director of MonashHeart, at Monash Medical Centre in Melbourne, Australia, and co-principal investigator for the PLATINUM clinical program, commented, 'The PLATINUM Small Vessel data continue to demonstrate very low revascularization rates, with no myocardial infarction or stent thrombosis through two years of follow up in patients treated with the 2.25 mm PROMUS Element Stent. These long-term results are impressive, especially considering the small vessel diameters that were evaluated in this study.'
Copyright RTT News/dpa-AFX
© 2012 AFX News
